Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients With Recurrent Glioblastoma (rGBM)

NCT07501559 is registered in ClinicalTrials.gov with Jecho Biopharmaceuticals Co., Ltd. as lead sponsor.

NCT NCT07501559
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07501559 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients With Recurrent Glioblastoma (rGBM)
Lead sponsor
Jecho Biopharmaceuticals Co., Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 17, 2026
Completion date
April 30, 2030
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent glioblastoma multiforme(gbm)